利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.024 秒)

    Neurodegenerative protein aggregation inhibition methods and compounds
    1.
    发明申请
    Neurodegenerative protein aggregation inhibition methods and compounds 失效
    神经变性蛋白聚集抑制方法和化合物

    公开(公告)号：US20050209173A1

    公开(公告)日：2005-09-22

    申请号：US10901848

    申请日：2004-07-28

    申请人： Isabella Graef ,  Gerald Crabtree ,  Jason Gestwicki

    发明人： Isabella Graef ,  Gerald Crabtree ,  Jason Gestwicki

    IPC分类号： A61K20060101 ,  A61K31/4745 ,  A61K31/5415 ,  A61K31/655 ,  A61K31/7076 ,  A61K47/48 ,  C12Q1/00

    CPC分类号： A61K31/4745 ,  A61K31/5415 ,  A61K31/655 ,  A61K31/7076 ,  A61K47/54

    摘要： Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl isomerase. By associating the aggregating forming proteins or neuronal cells under conditions where aggregating proteins are produced with the compound and the aggregation inhibiting protein, aggregation is reduced. The subject agents can be used in assays, investigating the etiology of the neuronal diseases and for prophylaxis and therapy.

    摘要翻译： 提供了用于减少与神经毒性相关的神经变性蛋白质的聚集或其它蛋白质的方法和组合物。 所述化合物包含用于结合靶向蛋白质的第一结构域或靶向元件，所述靶蛋白与结合至聚集抑制蛋白质的第二结构域或募集元件连接。 脯氨酰异构酶。 通过在与化合物和聚集抑制蛋白质产生聚集蛋白质的条件下缔合形成蛋白质或神经元细胞，聚集减少。 主题试剂可用于测定，研究神经元疾病的病因以及预防和治疗。

    Methods and agents for enhancing bone formation or preventing bone loss
    4.
    发明申请
    Methods and agents for enhancing bone formation or preventing bone loss 审中-公开
    增强骨形成或预防骨质流失的方法和试剂

    公开(公告)号：US20050171015A1

    公开(公告)日：2005-08-04

    申请号：US10978672

    申请日：2004-11-01

    申请人： Gerald Crabtree ,  Monte Winslow

    发明人： Gerald Crabtree ,  Monte Winslow

    IPC分类号： A61K38/18

    CPC分类号： A61K38/465 ,  A61K38/1709 ,  G01N33/5035 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/108

    摘要： The present invention provides methods for (i) reducing loss of bone mass or bone density, (ii) increasing bone mass or bone density, (iii) maintaining bone mass or bone density, and/or (iv) reducing loss of calcium from bone, comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. The method could be used for treating, preventing or delaying a bone condition. The invention further provides a method for promoting healing of bone fractures or bone defects comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. Compositions comprising NFAT agonists can also be used for the in vitro or in vivo generation of bone tissue. The invention also provides screening methods for agents which promotes, maintains, or reduces the loss of, bone mass, and the use of such agents for therapeutic purposes.

    摘要翻译： 本发明提供了（i）减少骨质量或骨密度损失的方法，（ii）增加骨质量或骨密度，（iii）维持骨量或骨密度，和/或（iv）减少骨骼中钙的损失 包括：向受试者施用治疗有效量的NFAT激动剂。 该方法可用于治疗，预防或延缓骨骼状况。 本发明进一步提供了促进骨折或骨缺损愈合的方法，其包括：向受试者施用治疗有效量的NFAT激动剂。 包含NFAT激动剂的组合物也可用于骨组织的体外或体内产生。 本发明还提供用于促进，维持或减少骨质量损失的试剂的筛选方法以及用于治疗目的的这些试剂的使用。

    Methods and compositions for enhancing neuron growth and survival
    5.
    发明申请
    Methods and compositions for enhancing neuron growth and survival 审中-公开
    用于增强神经元生长和存活的方法和组合物

    公开(公告)号：US20050014680A1

    公开(公告)日：2005-01-20

    申请号：US10824939

    申请日：2004-04-15

    申请人： Gerald Crabtree ,  Isabella Graef ,  Marc Lavigne

    发明人： Gerald Crabtree ,  Isabella Graef ,  Marc Lavigne

    IPC分类号： A61K38/18 ,  A61K38/46 ,  G01N33/74 ,  A61K38/28

    CPC分类号： G01N33/74 ,  A61K38/18 ,  A61K38/185 ,  A61K38/465 ,  C12Y301/03016 ,  G01N2500/10 ,  Y02A50/401 ,  Y02A50/57

    摘要： Pharmaceutical compositions of NF-AT agonists may be used to promote nerve regeneration or to reduce or inhibit secondary nerve degeneration which may otherwise follow primary CNS or PNS injury, e.g., trauma (e.g., blunt trauma, penetrating trauma), compression [e.g., compression due to tendons and/or inflamed synovial membrane such as in carpal tunnel syndrome], bones [for instance sciatica], or growths [benign or cancerous, including growth of the nerves themselves or of surrounding tissue]) hemorrhagic stroke, ischemic stroke or damages caused by surgery such as tumor excision. In certain embodiments, NF-AT agonists may be used to treat spinal cord injuries and promote nerve grafts.

    摘要翻译： NF-AT激动剂的药物组合物可用于促进神经再生或减少或抑制继发性神经变性，否则可能会继发于原发性CNS或PNS损伤，例如创伤（例如钝性创伤，穿透性创伤），压迫 由于肌腱和/或发炎滑膜如腕管综合征]，骨骼（例如坐骨神经痛）或生长[良性或癌性，包括神经本身或周围组织的生长]）出血性中风，缺血性卒中或损伤 引起手术如肿瘤切除。 在某些实施方案中，NF-AT激动剂可用于治疗脊髓损伤并促进神经移植物。

    Conditional allele system
    7.
    发明申请
    Conditional allele system 审中-公开
    条件等位基因系统

    公开(公告)号：US20050214738A1

    公开(公告)日：2005-09-29

    申请号：US10992304

    申请日：2004-11-17

    申请人： Kryn Stankunas ,  Jason Gestwicki ,  Kelvin Neu ,  Gerald Crabtree ,  Joseph Bayle

    发明人： Kryn Stankunas ,  Jason Gestwicki ,  Kelvin Neu ,  Gerald Crabtree ,  Joseph Bayle

    IPC分类号： C07H21/04 ,  C07K20060101 ,  C07K14/47 ,  C12N15/00 ,  C12N15/09 ,  C12N15/62 ,  C12N15/85 ,  C12N15/86 ,  C12P21/04 ,  C12Q1/00 ,  G01N33/50

    CPC分类号： C07K14/4702 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  C07H21/04 ,  C07K2319/95 ,  C12N9/1205 ,  C12N15/62 ,  C12N15/8509 ,  G01N33/5041

    摘要： A conditional allelic system is provided where recombinant cells express a fusion protein, where the fusion protein comprises at least a functional portion of a target protein and a destabilizing peptide. The destabilizing peptide binds to a small stabilizing molecule that results in the stabilization of the fusion protein in a functional form, while in the absence of the small stabilizing molecule, the protein function is substantially reduced. The system finds use in studying cellular pathways, preparing transgenic animals that can develop in the presence of the small stabilizing molecule and can then be studied in the presence and absence of the fusion protein to determine the functions and/or effects of target protein function in and/or on various environments. Specifically, a mutated peptide from mTOR is employed as the destabilizing peptide and a modified rapamycin is employed as the small stabilizing molecule.

    摘要翻译： 提供条件等位基因系统，其中重组细胞表达融合蛋白，其中融合蛋白包含至少一种靶蛋白的功能部分和去稳定肽。 去稳定肽结合到导致功能性形式的融合蛋白稳定化的小稳定分子，而在不存在小稳定分子的情况下，蛋白质功能显着降低。 该系统用于研究细胞途径，制备可在小稳定分子存在下发展的转基因动物，然后可以在存在和不存在融合蛋白的情况下研究，以确定靶蛋白功能的功能和/或效应 和/或在各种环境中。 具体地，使用来自mTOR的突变肽作为去稳定肽，并且使用修饰的雷帕霉素作为小稳定分子。

    Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
    8.
    发明申请
    Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug 有权
    通过施用含有该药物的双官能分子来调节药物的药代动力学性质

    公开(公告)号：US20050209265A1

    公开(公告)日：2005-09-22

    申请号：US11011776

    申请日：2004-12-13

    申请人： Roger Briesewitz ,  Gerald Crabtree ,  Thomas Wandless

    发明人： Roger Briesewitz ,  Gerald Crabtree ,  Thomas Wandless

    IPC分类号： A61K47/48 ,  A61K31/4745

    CPC分类号： A61K47/55 ,  A61K47/54 ,  Y10S530/812

    摘要： Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic property upon administration to a host as compared to a free drug control. The subject bifunctional molecules find use in a variety of therapeutic applications.

    摘要翻译： 提供了双功能分子及其使用方法。 主题双功能分子是药物部分和药代动力学调节部分的缀合物，其中这两个部分任选地通过连接基团连接。 双官能分子的特征还在于，与游离药物对照相比，它们在施用于宿主时表现出至少一种调节的药代动力学性质。 主题双功能分子可用于各种治疗应用。